Curcumin spice linked to slowing of lung lining cancer

Image
ANI Washington
Last Updated : Sep 22 2014 | 5:37 PM IST

A new study has revealed that Asian spice Curcumin show promise in slowing the progression of mesothelioma, a cancer of the lung's lining often linked to asbestos.

According to the study by scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, the spice which is a derivative of the spice turmeric and cancer-inhibiting peptides, increase levels of a protein inhibitor known to combat the progression of this cancer.

Researcher Afshin Dowlati said that mesothelioma is a disease that continues to have a significant burden worldwide, and the treatment option is really suboptimal and they now understand the mechanisms that drive cell proliferation and growth in malignant mesothelioma.

Investigators also found that curcumin and PIAS3 peptides raised PIAS3 levels, which brought down STAT3 activity and caused mesothelioma cells to die. Their study served as proof of principle about the effectiveness of these two compounds in treating malignant mesothelioma, a first step in moving a treatment toward clinical trials. Additionally, their findings demonstrated that PIAS3 could serve as a predictive marker for managing mesothelioma because the disease's tumors do not always progress in a consistent, predictable manner, even when tumor stages, grades and clinical presentations appear similar.

Researchers said that their findings suggest that PIAS3 expression positively affects survival in mesothelioma patients and that PIAS3 activation could become a therapeutic strategy and their interest for the future is that they want to find better, more simple ways to increase intracellular levels of PIAS3 for malignant mesothelioma through the use of synthetic PIAS3 peptide or curcumin analogs. They must develop a curcumin analog that is absorbable by the human body. Currently, curcumin ingested as the spice turmeric has practically no absorption within the gut.

The study was published online in Clinical Cancer Research.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 22 2014 | 5:23 PM IST

Next Story